Table 3.

Adverse events

Study	Reported adverse events
Fregni F, et al. Inter Jrl Neuropsychopharm. 2006 [24]	N = 54; Included headache, neck pain and scalp burn
Brakemeier E-L, et al. Jrl. Psych Res. 2007 [30]	Not a defined endpoint.
O’Reardon JP, et al. Biol Psych. 2007 [25]; Lisanby SH, et al. Neuropsychopharm. 2009 [18]	Active rTMS: eye pain (n = 10); GI & toothache (n = 12); site discomfort (n = 18); site pain (n = 59); facial pain (n = 11); muscle twitching (n = 334); pain of skin (n = 14).
	Sham: eye pain (n = 3); GI & toothache (n = 1); site discomfort (n = 2); site pain (n = 6); facial pain (n = 5); muscle twitching (n = 5); pain of skin (n = 1)
Brakemeier E-L, et al. Jrl Affect Disord. 2008 [31]	Not a defined endpoint
Cohen RB, et al. Jr. Nerv Ment Dis. 2010 [32]	Headache (n = 6); increased somnolence (n = 2); nightmares (n = 3)
Carpenter LL, et al. Depress Anxiety. 2012 [33]	Tonic/clonic seizure (n = 1)
Huang M-L, et al. Aust & NZ Jrl Psych. 2012 [26] (Note: Huang L et al., Zhejiang Da Xue Bio Yi Xue Ban. 2011 is a duplicate study [43]. However it is in Chinese so Huang M-L et al. Aust & NZ Jrl Psych 2012 used)	Not a defined endpoint
Wang H-N, et al. Translational Psych. 2017 [27]	rTMS + meds: diarrhea (n = 5); constipation (n = 28); dry mouth (n = 43); nausea (n = 3); palpitations (n = 11); dizziness (n = 8); headache (n = 6); blurred vision (n = 21); tinnitus (n = 14).
	Meds: diarrhea (n = 8); constipation (n = 35); dry mouth (n = 66); nausea (n = 8); palpitations (n = 9); dizziness (n = 8); headache (n = 2); blurred vision (n = 15); tinnitus (n = 3).
Wang Y-M, et al. Psych Res. 2017 [28]	Active rTMS: headache/scalp pain (n = 7); Sham: headache/scalp pain (n = 8)
Yang H, et al. Jrl Psych Brain Sci. 2017 [29]	Active rTMS: scalp pain & dizziness (n = 2)